Introduction
============

Patients with chronic kidney disease (CKD) exhibit major proatherogenic lipid abnormalities that are associated with their prognosis ([@b1-ijmm-42-05-2720]). The severe disorder of lipoprotein metabolism in patients with CKD typically manifests as higher triglyceride (TG) levels and lower levels of high-density lipoprotein cholesterol (HDL-C) ([@b1-ijmm-42-05-2720]). Dyslipidemia also increases the incidence of coronary atherosclerosis and cardiovascular events. Notably, improving hyperlipidemia may reduce dialysis morbidity and mortality in patients with end-stage renal disease.

Notably, the mechanisms of dyslipidemia in nephrotic syndrome (NS) are associated with hepatic biology, including liver lipid regulatory enzymes, activity of low-density lipoprotein (LDL) receptors and compensatory synthesis in the liver ([@b2-ijmm-42-05-2720]). Liver-associated physiological processes exhibit rhythmicity, and the circadian rhythm activities are regulated by central and hepatic-specific clock systems ([@b3-ijmm-42-05-2720]).

Diurnal oscillations are regulated by conserved clock genes in the organism, which act as a hierarchical, collaborative, large-scale \'circadian time\' ([@b4-ijmm-42-05-2720]). The majority of biological processes, including the maintenance of blood pressure, sleeping and respiratory rhythm, exhibit circadian rhythmicity, and are also regulated by clock genes ([@b5-ijmm-42-05-2720]). These genes are expressed in all cell types, including the \'master clock\' located in the suprachiasmatic nucleus and the peripheral clock in locations, such as the kidney and liver ([@b4-ijmm-42-05-2720]). A previous study indicated that genomic transcription was highly rhythmic, with ≤81.7% of protein-coding genes exhibiting daily rhythms in expression ([@b6-ijmm-42-05-2720]). These oscillators dominate the rhythmic expression of downstream clock-regulated genes, accounting for 10--15% of the genes that regulate the circadian characteristics of the physiological functions of peripheral organs ([@b7-ijmm-42-05-2720]).

The cell-autonomous molecular clock in mammals is generated by two interlocking transcription/translation feedback loops (TTFLs) that cooperate to produce robust rhythms of gene expression. The core TTFL is driven by two activators, circadian locomoter output cycles kaput (*CLOCK*) and brain and muscle ARNT-like protein 1 (*BMAL1*), and two repressors cryptochrome (*CRY*) and period homologue (*PER*) ([@b8-ijmm-42-05-2720]), which aid the organism to drive circadian rhythms of behavioral activity and hormones ([@b9-ijmm-42-05-2720]). Previous studies have confirmed that the hepatic clock maintains normal glucose (GLU) levels, fatty acids, fat mobilization and the rhythm of other biochemical reactions in a steady state through the liver X receptor (LXR), peroxisome proliferator-activated receptor (PPAR) γ coactivator and PPAR signaling pathways to regulate TG, cholesterol and fat metabolism under physiological conditions ([@b3-ijmm-42-05-2720],[@b10-ijmm-42-05-2720]).

The clock system serves an essential role in homeostasis. Notably, dyslipidemia is considered a homeostasis disorder event in NS. However, the effects of the circadian rhythmicity on blood lipids and the hepatic clock system in this context are unclear. Therefore, the present study was performed to observe the circadian rhythm of lipids and clock genes associated with lipid metabolism in Adriamycin (ADR)-induced nephropathy in rats to explore the potential effects of the clock system on lipid metabolism abnormalities.

Materials and methods
=====================

Experimental animals and treatment protocol
-------------------------------------------

A total of 36 adult male Sprague Dawley rats (8-weeks old; 245--265 g) were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China). The animal experimental procedures were approved by the Animal Ethics Committee of Peking Union Medical College Hospital (PUMCH; Beijing, China). Furthermore, all experiments were performed according to international and institutional guidelines for animal care ([@b11-ijmm-42-05-2720]), and approved by the PUMC Committee on Animal Care and Use. All rats had access to standard food and tap water *ad libitum*. Rats were housed at 23±2°C ([@b12-ijmm-42-05-2720],[@b13-ijmm-42-05-2720]), under a strict 12-h light/dark regimen whereby zeitgeber time ZT0-ZT12 with the lights on represented the resting phase of the day and ZT12-ZT0 with the lights off represented the active phase of the day. Following 2 weeks of adaptation, rats were randomly divided into two groups: ADR group (ADR-induced nephropathy rats) and control group (saline-treated rats). The NS model was established 14 days from the single intravenous tail injection of 6.5 mg/kg ADR (dissolved in saline; Pfizer, Inc., New York, NY, USA) according to the protocol by Bertani *et al* ([@b14-ijmm-42-05-2720]). Rats in the control group were injected with an equal volume of saline only. The experimental animals were fasted in a metabolic cage to assess 24-h urine excretion. A 24-h urine excretion value of \>100 mg ([@b15-ijmm-42-05-2720]) and foot process effacement of renal tissues detected by electron microscopy ([@b16-ijmm-42-05-2720]) indicated the successful establishment of the NS model. After 2 weeks, the rats from the two groups were sampled every 4 h over 24 h (3 rats/group at each time point, with a total of 18 normal rats and 18 NS rats). During the sacrificed day, standard food and water was provided *ad libitum* and treatments were quickly finished to minimize the impact on the timer giver and animal, consistent with other literature methodologies ([@b12-ijmm-42-05-2720],[@b13-ijmm-42-05-2720]). The handling of rats during the dark time period was performed under a dim red light, which does not influence endogenous melatonin production ([@b17-ijmm-42-05-2720]).

Blood samples and liver tissue
------------------------------

Rats from each group were sacrificed at ZT 2:00, 6:00, 10:00, 14:00, 18:00 and 22:00 h. The liver tissues were immediately frozen in liquid nitrogen and stored in RNAlater (cat. no. AM7020; Ambion; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at −80°C. Blood samples were centrifuged at 6,391 × g for 10 min at 4°C. Samples were sent to the Department of Laboratory Medicine, PUMCH (Beijing, China). The following measurements were performed with a Hitachi Modular P800 analyzer (Hitachi, Ltd., Tokyo, Japan): Serum total cholesterol (TC) (CHOD-PAP method; Roche Diagnostics GmbH, Mannheim, Germany) ([@b18-ijmm-42-05-2720]), serum TGs (GP0-PAP method; Roche Diagnostics GmbH), and HDL-C (Roche HDL-C Plus 2nd generation kit; Roche Diagnostics GmbH). LDL-C was calculated using the Friedewald formula ([@b19-ijmm-42-05-2720]). Albumin was measured using the bromopotassium phenol green method ([@b20-ijmm-42-05-2720]) and serum creatinine was measured using a sarcosine oxidase method ([@b21-ijmm-42-05-2720]). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity was assessed with an automatic biochemical analyzer. Furthermore, GLU levels were measured using the hexokinase method ([@b22-ijmm-42-05-2720]).

Transmission electron microscopy analyses
-----------------------------------------

Fresh rat renal tissues were removed in sections of \~2.0 mm^3^ and fixed with 2.5% glutaraldehyde in 0.1 M Sorenson\'s phosphate buffer (pH=7.41) for 2 h at 4°C. Following this, the samples were washed three times with 0.1 M Sorenson\'s phosphate buffer. The tissues were subsequently post-fixed for 1--1.5 h in 1% OsO~4~ in 0.l M Sorenson\'s phosphate buffer, washed with distilled water, then stained *en bloc* with 3% uranyl acetate for 30 min at 25°C. Dehydration was performed using a 50--95% graded ethanol series, followed by two changes in propylene oxide. Sections of 70--80 nm were cut, and collected on a 200 copper/rhodium grid stained with uranyl acetate and lead citrate. Following this, samples were observed under a transmission electron microscope (magnification, ×5,000).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis
-------------------------------------------------------------------------------

Total RNA was extracted from frozen heart tissues using RNAiso Plus reagents (cat. no. 9109; Takara Bio, Inc., Otsu, Japan) according to the manufacturer\'s protocol. RNA was reverse transcribed using the PrimeScript^®^ RT Master Perfect Real-time kit (cat. no. DRR036A; Takara Bio, Inc.). The resulting cDNA was amplified using a SYBR-Green PCR kit (cat. no. DRR082A; Takara Bio, Inc.) and detected with a 7500 Fast Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). All experiments were performed at least three times according to the manufacturer\'s protocol. The conditions for the two-step amplification PCR reaction were pre-denaturation (95°C, 30 sec, 1 cycle) and PCR amplification (95°C, 5 sec and 60°C, 30 sec, 40 cycles). Gene expression was calculated relative to the housekeeping gene *GAPDH* using the 2^−ΔΔCq^ method ([@b23-ijmm-42-05-2720]). The primers used for PCR are presented in [Table I](#tI-ijmm-42-05-2720){ref-type="table"}.

Protein-protein interaction (PPI) network and functional enrichment of protein-coding genes
-------------------------------------------------------------------------------------------

Due to the difficulties of obtaining human tissues to explore the rhythmic characteristics of clock gene expression levels every 4 h, correlation analyses of the expression levels of human proteins were performed using the STRING database (<http://www.string-db.org/>) ([@b24-ijmm-42-05-2720]) as a complementary platform to assessed the association between core clock and clock-controlled genes in patients with renal disease. Furthermore, the DAVID Bioinformatics Tool ([@b25-ijmm-42-05-2720]) was used to identify functional enrichment of target protein-coding genes. Notably, this tool may be used to identify Gene Ontology (GO) biological processes associated with protein-coding genes. Furthermore, KEGG pathway enrichment analysis was performed using KOBAS 3.0 (<http://kobas.cbi.pku.edu.cn/>). Cytoscape ([www.cytoscape.org/](http://www.cytoscape.org/)) ([@b26-ijmm-42-05-2720]) was also used to visualize the above biological process organization and GOplot (<http://wencke.github.io/>) ([@b27-ijmm-42-05-2720]) was used to illustrate the functional analysis data.

Statistical analysis
--------------------

The results are presented as the mean ± standard deviation, and the data were analyzed using unpaired t-tests with SPSS 20.0 software (IBM Corp., Armonk, NY, USA) for comparisons between groups. P\<0.05 was considered to indicate a statistically significant difference. Gene expression data and blood parameters were analyzed to assess the circadian rhythmicity of data using a Fourier transform method and Chronos-Fit software (<http://chronos-fit.software.informer.com/>). Following the Chronos-Fit software formula: F(t)=mesor+Σ (amplitude~i~ × cos (t-acrophase~i~) × 2π/pi). The parameters included the mean, midline estimating statistic of rhythm (mesor), amplitude of the sine wave (amplitude) and the acrophase or time of maximum of the sine wave (acrophase). The chart indicated the curve fitted to the circadian analysis of all clock genes. Significance (P\<0.05) was evaluated using the F-test as described previously ([@b28-ijmm-42-05-2720],[@b29-ijmm-42-05-2720]).

Results
=======

Rats with nephropathy exhibit hyperglycemia and disordered rhythms in serum TC, TG, AST and ALT levels
------------------------------------------------------------------------------------------------------

The ADR-induced nephropathy model is a classical nephropathy animal model ([@b16-ijmm-42-05-2720],[@b30-ijmm-42-05-2720]). In the present study, 2 weeks following ADR injection, the ADR group presented with minimal change in disease according to the electron microscopy results ([Fig. 1](#f1-ijmm-42-05-2720){ref-type="fig"}). The levels of blood TC, TG, HDL-C, LDL cholesterol (LDL-C) and GLU over 24 h were significantly increased in the ADR group compared with the control group (all P\<0.05, [Table II](#tII-ijmm-42-05-2720){ref-type="table"}). AST and ALT activity was also significantly increased in the ADR group compared with the control group (P\<0.05, [Table II](#tII-ijmm-42-05-2720){ref-type="table"}). In the control group, the serum levels of TC, TG, AST and ALT were significantly cycled every 12, 24, 24 or 24 h, respectively (all P\<0.05), and the double amplitudes (2A) of the TC and TG levels were similar (2A=0.78). However, in the ADR group, the rhythm of the TG levels changed from the baseline of 24 to 12 h, and no oscillations were observed with regards to TC, AST and ALT levels (all P\>0.05; [Fig. 2](#f2-ijmm-42-05-2720){ref-type="fig"}). The HDL-C, LDL-C and GLU levels in the two groups did not indicate a circadian rhythm (F-test, P\>0.05; data not shown).

Hepatic core clock and clock-controlled genes that regulate TG, cholesterol and fat metabolism are associated with disordered rhythms in NS rats
------------------------------------------------------------------------------------------------------------------------------------------------

The circadian rhythm of six hepatic core clock genes and six clock-controlled genes associated with metabolism were evaluated. The data revealed the *CRY1* and *PER2* genes exhibited 24-h rhythmicity, and their peak times advanced by 0.5 and 2.5 h compared with those in the control group; however, the rhythm *of PER1* mRNA expression was wholly absent in the ADR group (P\<0.05). Other core clock genes, including CLOCK and *CRY2*, exhibited a change in periodicity from 24 to 12 h, and their peak times significantly shifted to the rest period (daytime; P\<0.05). Furthermore, the rhythm of *BMAL1* mRNA expression changed from 24 h to a period of 4.8+6 h (P\<0.05; [Fig. 3A](#f3-ijmm-42-05-2720){ref-type="fig"}).

The liver-specific clock-controlled genes, including *LXR*, cholesterol 7α-hydroxylase (*CYP7A1*), sterol regulatory element binding protein-1c (*SREBP-1*), ATP binding cassette transporter A1 (*ABCA1*) and the basic helix-loop-helix transcription factors, differentiated embryo chondrocyte1 (*DEC1*) and *DEC2*. The rhythms of the mRNA expression levels of *DEC1, DEC2, SREBP-1 and ABCA1* were completely absent in the livers in the ADR group (P\<0.05). Although *LXR* and *CYP7A1* maintained circadian rhythm characteristics, the time periods in the ADR group compared with the control rats changed for *LXR* (from 24 h to 12+24 h) and *CYP7A1* (from 4.8 to 24 h; all P\<0.05; [Fig. 3B](#f3-ijmm-42-05-2720){ref-type="fig"}).

Functional annotation and PPI network construction
--------------------------------------------------

Highly associated genes in a given genetic module serve important roles in biological processes ([@b31-ijmm-42-05-2720]). Therefore, the six aforementioned hepatic core clock genes and six clock-controlled genes that were highly associated with the hepatic circadian rhythms of blood lipid metabolism were selected, and PPI networks were constructed using STRING ([@b32-ijmm-42-05-2720]). These genes in the PPI network were identified to have stronger interactions among themselves (average local clustering coefficient, 0.849; [Fig. 4](#f4-ijmm-42-05-2720){ref-type="fig"} and [Table III](#tIII-ijmm-42-05-2720){ref-type="table"}[](#tIV-ijmm-42-05-2720){ref-type="table"}). Notably, the PPI network of STRING v10 makes use of all microarray gene expression experiments deposited in the NCBI Gene Expression Omnibus to provide co-expression analysis, which is a reliable indicator of functional associations ([@b33-ijmm-42-05-2720]).

To gain insight into the functional characteristics of the identified blood lipid metabolism-associated protein-coding core clock and clock-controlled genes, GO and KEGG pathway enrichment analyses were performed using DAVID ([@b34-ijmm-42-05-2720]). Molecular information was added to GO terms of potential associated genes of circadian rhythms of blood lipid metabolism ([Fig. 5](#f5-ijmm-42-05-2720){ref-type="fig"}). In terms of biological processes, the GO analysis indicated that the clock system protein-coding genes were significantly (all P\<0.05) enriched in the circadian regulation of gene expression (GO:0006351), the negative regulation of the glucocorticoid receptor signaling pathway (GO:2000323) and DNA-templated transcription (GO:0045892). In terms of molecular function (MF), the genes were enriched in E-box binding (GO:0070888), transcription factor activity and transcription factor binding (GO:0000989), and transcription regulatory region sequence-specific DNA binding (GO:0000976). Additionally, GO cellular component (CC) analysis revealed that the genes were significantly enriched in the nucleus, chromatoid body and intracellular membrane-bound organelles.

Additionally, a graphic representation of the complicated association between clock genes and the respective GO terms, including a \'concept-and-gene network\', was constructed using the GeneAnswers R package ([@b35-ijmm-42-05-2720]). To add quantitative molecular data to the GO terms of interest, the GOCircle plot, GOChord and GOCluster plot functions of the *GOplot* R package were added ([@b27-ijmm-42-05-2720]) ([Figs. 6](#f6-ijmm-42-05-2720){ref-type="fig"} and [7](#f7-ijmm-42-05-2720){ref-type="fig"}). These functions permit the incorporation of data derived from expression level measurements with those obtained from functional annotation enrichment analysis (Table IV).

According to the interactions between the clock genes and the intersecting pathway genes, a clock gene network was constructed that illustrated the network pathway and the key regulatory functions of the identified clock genes. Using KEGG pathway enrichment analysis of Cytoscape and the KOBAS network, the rhythmically expressed protein-coding genes were determined to be significantly enriched in circadian rhythm (hsa04710), PPAR signaling pathways (hsa03320), circadian entrainment (hsa04713), fat digestion and absorption (hsa04975) and ABC transporters (hsa02010); [Fig. 8](#f8-ijmm-42-05-2720){ref-type="fig"} and [Table V](#tV-ijmm-42-05-2720){ref-type="table"}).

Discussion
==========

The majority of studies suggest that the lipid metabolism involved in kidney disease primarily affects local tissue lipid deposition and local tissue energy barriers ([@b36-ijmm-42-05-2720]). However, serum cholesterol levels of patients with CKD are determined by endogenous synthesis and intestinal absorption of exogenous cholesterol ([@b37-ijmm-42-05-2720]). Although numerous tissues (endocrine organs, the immune system, the endothelium) contribute to the plasma protein pool, the bulk of plasma proteins is secreted by the liver and are those lost to the highest extent in the NS ([@b38-ijmm-42-05-2720]). Additionally, three-quarters of the total cholesterol is synthesized in the liver ([@b39-ijmm-42-05-2720]), thus, it was hypothesized that renal injury affects peripheral blood lipid levels through the liver. Therefore, the present study focused on the hepatic clock system that affects circulating lipids.

Clinicians usually overlook the circadian rhythm of blood lipids. Few primary research studies have explored the circadian rhythm of blood lipids ([@b40-ijmm-42-05-2720]--[@b42-ijmm-42-05-2720]). However, previous studies have suggested that the deletion or knockdown of mouse core clock genes results in several circadian rhythm abnormalities concerning TGs, gluconeogenesis and liver GLU metabolism ([@b40-ijmm-42-05-2720],[@b43-ijmm-42-05-2720]). It is well acknowledged that hyperlipidemia occurs in patients with NS and improves immediately with the remission of NS. It is an excellent model of kidney disease to explore the circadian rhythm of blood lipids, and the underlying crosstalk between kidney and liver.

In the present study, nephropathy induced by ADR in rats presented with the typical characteristics of normal renal function, hypoalbuminemia and hyperlipidemia. Electron microscopy indicated partial podocyte fusion, which is a major cause of idiopathic NS. Multiple and large doses (total \>10 mg/kg) of Adriamycin are associated with the development of rat hepatic lesions ([@b44-ijmm-42-05-2720]), whereby Adriamycin causes significant abnormalities in liver function parameters. In previous studies, the single dose of Adriamycin generally used in rats to induce NS is between 5.0 and 7.5 mg/kg ([@b16-ijmm-42-05-2720],[@b45-ijmm-42-05-2720],[@b46-ijmm-42-05-2720]). Since complete absorption of the drug may induce organ damage, intravenous injection provides direct access to the drug and eliminates the absorption dependence on the peritoneal membrane ([@b46-ijmm-42-05-2720]). Therefore, the present study used a single tail vein injection dose of 6.5 mg/kg the day after 2 weeks of adaptation and particular caution was taken due to the risk of extravasation during injection. The ADR-induced nephropathy rats exhibited significantly higher blood lipid levels and a disturbed blood lipid circadian rhythm (P\<0.05). Notably, the activities of AST and ALT in the ADR group were not pathologically increased, whereby the levels were within the normal range of male rats aged 12--13 weeks (normal ranges: AST, 87-144 U/l; ALT, 28-40 U/l) ([@b23-ijmm-42-05-2720]). The NS rats in the present study may not have experienced deterioration in hepatic function, because the levels of ALT and AST remained within the normal range compared with the control group, and the total dose of Adriamycin was less than the dose required to induce liver damage. Dyslipidemia may be attributed to the compensatory liver dysfunction under the nephritic state. However, the lack of histological staining of liver tissue in the same set of experiments was a limitation of this study.

Multiple regulators of lipid metabolism and rate-limiting enzymes in TG accumulation exhibit circadian rhythmicity during nutrient metabolism, and the clock system is indispensable for these processes in the liver. Mice lacking the liver-specific core clock gene *BMAL1* exhibit abnormalities in blood TGs, GLU and gluconeogenesis. Furthermore, a previous study revealed the metabolism-associated clock-controlled genes altered rhythms; however, the rhythm of GLU remained consistent in the asynchronous dietary ([@b47-ijmm-42-05-2720]). Human plasma lipid levels, including those of TGs and cholesterol, are rhythmic over a 24-h period ([@b48-ijmm-42-05-2720]), independent of feeding and waking conditions ([@b42-ijmm-42-05-2720]). Furthermore, Chua *et al* ([@b42-ijmm-42-05-2720]) did not detect a circadian rhythm in blood GLU and LDL-C; however, a trend was observed for higher levels of LDL-C during the daytime, this may be due to substantial individual differences in timing of the rhythm. Their results are consistent with the present study; however, they did not evaluate a rhythmic component via the Fourier transform method. Significant daily variations in the HDL-C levels were detected by Rivera-Coll *et al* ([@b48-ijmm-42-05-2720]) and Van den Berg *et al* ([@b49-ijmm-42-05-2720]). However, Van Den Berg *et al* ([@b49-ijmm-42-05-2720]) did not evaluate a rhythmic component. Notably, different analytical methods in other studies make it difficult to compare the result that lack of circadian rhythm associated with HDL-C levels in the present study; a fact that may explain, in part, the observed differences in timing and daily amplitude between the present research and other studies. A previous study indicated *CLOCK* knockout mice exhibit hyperlipidemia and hepatic steatosis, and *PER1* regulates *PPARα* mRNA expression and the development of obesity ([@b41-ijmm-42-05-2720]). Furthermore, *PER2* has been suggested to be involved in PPAR-associated pathways and white adipose tissue mobilization ([@b3-ijmm-42-05-2720]). The aforementioned studies suggested that different circadian clock genes serve a role in the regulation of lipid regulation.

In the present study, the mRNA expression of six hepatic core clock genes in the normal control group was associated with stable rhythmic features, with minimums during the day and maximums at night (activity period), which is consistent with previous studies on mice ([@b50-ijmm-42-05-2720],[@b51-ijmm-42-05-2720]). Furthermore, the cycle duration was 24 h for five core clock genes (*CLOCK*, *BMAL1*, *PER2*, *CRY1* and *CRY2*) and 12 h for *PER1* in the control group. However, extended or abnormal rhythms were exhibited in the ADR group. Although *PER1* mRNA was expressed in the ADR group, the rhythm was absent (P\<0.05). In addition, disordered rhythms were revealed in the downstream lipid-associated clock-controlled genes of core hepatic clock genes (*LXR*, *DEC1*, *DEC2*, *SREBP-1*, *ABCA1* and *CYP7A1*). Among these, the rhythmic expression of functional clock genes (*DEC1* and *DEC2*), as well as *PER1,* was entirely absent in the ADR group. Notably, the former two genes are downstream of the core clock gene *PER1* and regulate feedback of *PER1* transcription ([@b52-ijmm-42-05-2720]). *CYP7A1*, *SREBP-1* and *ABCA1* all exhibit periodic oscillations, and are regulated by *DEC1* and *DEC2* ([@b53-ijmm-42-05-2720]). CYP7α serves important roles in bile acid synthesis and its rhythmic expression is inhibited by binding DEC2 via E-box elements. The present finding supports that increasing hepatic *DEC2* mRNA expression may result in a reduction in *CYP7α* mRNA expression in NS rats. This may hinder the metabolism of cholesterol into bile acids, thereby inducing the occurrence of hypercholesterolemia. LXRα increases *CYP7α* expression and promotes bile acid synthesis ([@b54-ijmm-42-05-2720]). ABCA1 typically mediates the transmembrane transport of lipids metabolites ([@b55-ijmm-42-05-2720]), serving a key role in the reverse transport of cholesterol *in vivo*. It also permits intracellular cholesterol, phospholipid and free ApoA or ApoE binding to LXRα, which then initiates HDL synthesis. In addition, several fatty acid synthase genes are target genes of *SREBP-1*, and the activity of *SREBP-1* leads to an increase in blood TG synthesis. The present study indicated that the circadian rhythmic expression of lipid metabolism genes was regulated by the critical rhythm of key enzymes and transcription-associated factors, and the associated fat synthase gene was simultaneously activated by the core clock genes ([Fig. 9](#f9-ijmm-42-05-2720){ref-type="fig"}).

Due to the limitation that human liver tissue cannot be extracted six times within 24 h to monitor blood lipid rhythm analysis, GO and KEGG enrichment assays were performed to detect differentially expressed clock genes to provide a biologically meaningful explanation of the present results in humans. Using bioinformatics methods, including the GOplot R package, for visually combining expression data with functional analysis and predicting the potential disease-causing genes has been considered viable in various diseases ([@b56-ijmm-42-05-2720],[@b57-ijmm-42-05-2720]). The enrichment of GO annotation terms revealed that the clock system protein-coding genes were significantly enriched in specific biological processes, MFs and CCs. In particular, the most representative functional processes of clock genes were the circadian regulation of gene expression, E-box binding, transcription factor activity and negative regulation of the glucocorticoid receptor signaling pathway. These findings were consistent with previous evidence that suggest the essential role of these pathogenetic mechanisms in disease states ([@b4-ijmm-42-05-2720],[@b5-ijmm-42-05-2720],[@b9-ijmm-42-05-2720]). However, the most significant limitation of the current research is the observational nature of the study *in vivo*, and the lack of specific knockdown and response experiments.

The functional interpretation of the GO- and KEGG-based clock-specific \'concept-and-gene networks\' in the present study highlighted the possibility that core clock genes exert pathogenic effects via different multifactorial combinations, providing an important insight into clock core genes that may have a fundamental influence in NS. The transcriptional amplitude of clock genes was decreased or absent in patients with NS included in this study, suggesting that these proteins may represent susceptibility factors for disordered rhythms.

To compensate for the difficulties and limitations of human circadian rhythm research, multiple bioinformatics methods were used to analyze the associations between the overall human core clock (*BMAL1*, *CLOCK*, *CRY1*, *CRY2*, *PER1* and *PER2*) and clock-controlled genes (*LXR*, *DEC1*, *DEC2*, *SREBP-1*, *ABCA1* and *CYP7A1*), including signaling pathway and correlation prediction analyses. Their associations in the co-expression network were determined (avg. local clustering coefficient, 0.849). Consistent with the KEGG pathway analysis results, these genes were primarily enriched in the circadian rhythm pathway, and governed the regulation of downstream liver-specific, lipid-associated clock-controlled genes and blood lipid homeostasis and rhythmicity. These results may aid in providing a deeper understanding of rhythmic gene expression in the human clock system.

From the publications reviewed, NS is one of the few acquired conditions that alter the plasma levels of lipoprotein ([@b58-ijmm-42-05-2720]). Once NS enters remission, lipoprotein levels normalize quickly ([@b38-ijmm-42-05-2720]), and the changes in hepatic circadian rhythm were demonstrated to be secondary to kidney disease without any damage to liver tissue in the present study. Since the molecular mechanism of the circadian rhythm of an organism involves the clock gene system, and the activity of peripheral clock systems are independent from the central clock system, the present study results suggested that renal injury lead to local circadian system disorder, which may have caused the impaired function of the core clock gene to affect the liver, subsequently disrupting lipid metabolism. In order to confirm the phenomenon observed in the present study, further studies are required.

In conclusion, the present study reported that NS rats exhibited dyslipidemia and circadian disorders of lipid metabolism. The results suggested that these changes involve the abnormal expression of hepatic core clock genes and downstream clock-controlled genes. Furthermore, the findings indicated that damage to the hepatic clock system is a potential molecular mechanism for disordered blood lipid circadian rhythm in the context of CKD. Such analyses offer a starting point for understanding the crosstalk between peripheral organs and peripheral clock systems. Further investigations into the prevention and treatment of CKD by resetting or repairing disturbed central or peripheral clock systems are required.
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![Electron microscopic observation of extensive foot process fusion in renal tissue of Adriamycin-induced nephropathy rats (red arrow).](IJMM-42-05-2720-g00){#f1-ijmm-42-05-2720}

![TC, TG, AST and ALT levels are associated with a circadian pattern. Arrows in each figure indicate the ZT was associated with the peak value and off-peak value of the fitted curve (acrophase). The chart shows the fitted curve generated by circadian analysis of all clock genes; this curve was checked for significance using the F-test (P\<0.05). 2A1 is the double amplitude of the control group, and 2A2 is the double amplitude of the ADR group. Gray area, dark period (ZT=12:00-24:00); white area, light period (ZT=00:00--12:00). The blue and red dots indicate the measured TC, TG, AST and ALT levels in the control and ADR groups during the light and dark periods, respectively. Partial Fourier analysis, n=36, three rats/group every 4 h in 24 h. ADR, Adriamycin-induced nephropathy; TC, total cholesterol; TG, triglyceride; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ZT, Zeitgeber time.](IJMM-42-05-2720-g01){#f2-ijmm-42-05-2720}

![Circadian pattern expressions. (A) Circadian pattern expression of hepatic core clock genes: *CLOCK* and *BMAL*; and two repressors *CRY* and *PER*. (B) Circadian pattern expression of clock-controlled genes: *LXR, CYP7A1, SREBP-1* and *ABCA1*; and the basic helix-loop-helix transcription factors, *DEC1* and *DEC2*. The purple and red dots indicate the measured gene expression values in the control and ADR groups, respectively. ADR, Adriamycin-induced nephropathy; *CLOCK*, circadian locomoter output cycles kaput; *BMAL1*, brain and muscle ARNT-like protein 1; *CRY*, cryptochrome; *PER*, period homologue; *LXR*, liver X receptor; *CYP7A1*, cholesterol 7α-hydroxylase; *SREBP-1*, sterol regulatory element binding protein-1c; *ABCA1*, ATP binding cassette transporter A1; *DEC*, differentiated embryo chondrocyte.](IJMM-42-05-2720-g02){#f3-ijmm-42-05-2720}

![Protein‑protein interaction network constructed with the 12 clock and clock‑controlled genes. Genes were enriched in the differential pathways identified in the *Homo sapiens* genome (avg. local clustering coefficient, 0.849). The colored nodes/lines represent different proteins/protein‑protein interactions.](IJMM-42-05-2720-g03){#f4-ijmm-42-05-2720}

![Target gene counts of GO biological processes. The GO analysis results demonstrated that the clock system protein-coding genes were significantly enriched in the circadian regulation of gene expression (GO:0006351), negative regulation of glucocorticoid receptor signaling pathway (GO:2000323) and DNA-templated (GO:0045892) under BPs (light blue bar). Under MF (purple), the genes were enriched in E-box binding (GO:0070888), transcription factor activity, transcription factor binding (GO:0000989) and transcription regulatory region sequence-specific DNA binding (GO:0000976). Additionally, GO CC (dark blue bar) analysis revealed genes significantly were enriched in the nucleus, chromatoid body and the intracellular membrane-bounded organelle. GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.](IJMM-42-05-2720-g04){#f5-ijmm-42-05-2720}

![Functional characterization of differentially and rhythmically expressed protein-coding genes. GOCircle plot: The outer circle shows a scatter plot of the expression levels of rhythmically expressed clock-associated genes in each enriched GO term. Red circles indicate upregulation and blue circles indicate downregulation. The inner ring is a bar plot, where the height of the bar indicates the significance of the GO term (log10-adjusted P-value), and the color corresponds to the z-score: blue, decreased; red, increased; and white, unchanged. GO, Gene Ontology.](IJMM-42-05-2720-g05){#f6-ijmm-42-05-2720}

![Specific clock genes are involved in pathways. (A) GOChord plot: A plot indicated the association between statistically significant clock genes and their associated GO terms; the genes are associated via ribbons to their assigned terms. Blue-to-red coding next to the selected genes indicates the amplitude change (the difference between the expression amplitude in the two groups divided by the amplitude of the control group). A negative sign indicates a decrease and a positive sign indicates an increase. The outer ring shows the assigned functional terms. (B) GOCluster plot: A circular dendrogram of the clustering of the expression profiles. The inner ring shows the color-coded amplitude changes and the outer ring shows the assigned functional terms. The details are provided in Table IV.](IJMM-42-05-2720-g06){#f7-ijmm-42-05-2720}

![KEGG analysis was conducted using KOBAS 3.0 online software (<http://kobas.cbi.pku.edu.cn/>). KEGG pathway enrichment of significant rhythmically expressed protein-coding genes. The green node represents significant rhythmically expressed protein-coding genes. The red node represents enriched pathway symbols. The details are provided in [Table V](#tV-ijmm-42-05-2720){ref-type="table"}. KEGG, Kyoto Encyclopedia of Genes and Genomes.](IJMM-42-05-2720-g07){#f8-ijmm-42-05-2720}

![Diagram of liver clock gene and clock control gene association. The red line represents the promoting effect, the green line represents inhibition, and the black line represents transcription into protein. *CLOCK*, circadian locomoter output cycles kaput; *BMAL1*, brain and muscle ARNT-like protein 1; *CRY*, cryptochrome; *PER*, period homologue; *LXR*, liver X receptor; *CYP7A1*, cholesterol 7α-hydroxylase; *SREBP-1*, sterol regulatory element binding protein-1c; *ABCA1*, ATP binding cassette transporter A1; *DEC*, differentiated embryo chondrocyte.](IJMM-42-05-2720-g08){#f9-ijmm-42-05-2720}

###### 

Primers for reverse transcription-quantitative polymerase chain reaction.

  Gene        Forward (5′--3′)           Reverse (5′--3′)
  ----------- -------------------------- ---------------------------
  *GAPDH*     GACAACTTTGGCATCGTGGA       ATGCAGGGATGATGTTCTGG
  *CLOCK*     CATCGGCAGCAAGAAGAACT       CAAGATTCAGTCCAGGGTTTG
  *BMAL1*     CAACCCATACACAGAAGCAAAC     ACAGATTCGGAGACAAAGAGGA
  *PER1*      GAGGAGCCAGAGAGGAAAGAGT     TTGGTTGTGTTAGGAATGTTGC
  *PER2*      CTGGAAAGAACAGGAAACTGAA     GGGAACACAGGTAGTGGGTAAG
  *CRY1*      ATCTAGCCCGACATGCAGTT       TCGGCGTCAAGCAGTAATTC
  *CRY2*      ATTGAGCGGATGAAGCAGAT       TCTACACAGGAAGGGACAGATG
  *LXR*       CCTGATGTTTCTCCTGACTC       TGACTCCAACCCTATCCTTA
  *DEC1*      CCACCAAAAAGAGCCGAAT        ATAGAAGGGCAGGCAAAAGG
  *DEC2*      GAAGCGAGACGACACCAAG        TTTCAGATGTTCAGGCAGTAAGTC
  *SREBP-1*   GGAGCCATGGATTGCACATT       GGCCCGGGAAGTCACTGT
  *ABCA1*     CTTGCTTCCGTTATCCAACTCCAG   GCTGTAATGTTCTCAGGACCTTGTG
  *CYP7A1*    CCAAGTCAAGTGTCCCCCTCTA     GACTCTCAGCCGCCAAGTG

*CLOCK*, circadian locomoter output cycles kaput; *BMAL1*, brain and muscle ARNT-like protein 1; *CRY*, cryptochrome; *PER*, period homologue; *LXR*, liver X receptor; *CYP7A1*, cholesterol 7α-hydroxylase; *SREBP-1*, sterol regulatory element binding protein-1c; *ABCA1*, ATP binding cassette transporter A1; *DEC*, differentiated embryo chondrocyte.

###### 

Laboratory parameters in the two groups.

  Measure            SD rats (n=18)   ADR rats (n=18)                                                P-value
  ------------------ ---------------- -------------------------------------------------------------- ---------
  ALB (g/l)          29.78±2.13       22.14±2.75[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}      \<0.05
  SCr (*µ*mol/l)     34.05±13.94      39.06±7.59                                                     0.231
  BUN (mmol/l)       7.01±1.34        7.00±1.50                                                      0.968
  TC (mmol/l)        1.80±0.29        4.45±1.47[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}       \<0.05
  TG (mmol/l)        0.71±0.56        3.97±2.87[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}       \<0.05
  HDL-C (mmol/l)     0.59±0.09        1.27±0.38[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}       \<0.05
  LDL-C (mmol/l)     0.25±0.05        0.68±0.23[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}       \<0.05
  GLU (mg/dl)        176.64±21.55     336.89±102.65[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}   \<0.05
  AST (U/l)          88.30±16.73      120.51±22.85[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}    \<0.05
  ALT (U/l)          51.73±10.66      70.59±15.30[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}     \<0.05
  24 h UP (mg/day)   21.70±7.53       178.30±68.53[a](#tfn2-ijmm-42-05-2720){ref-type="table-fn"}    \<0.05

P\<0.05 (between-group comparison). Values are expressed as the mean ± standard deviation. ALB, albumin; SCr, serum creatinine; BUN, blood urea nitrogen; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GLU, glucose; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; 24 h UP, urine protein; SD, Sprague-Dawley control rats; ADR, Adriamycin-induced nephropathy.

###### 

Data of String interactions.

  \#node1   node2     node1_string_internal_id   node2_string_internal_id   node1_external_id      node2_external_id      neighborhood_on_chromosome   gene_fusion   phylogenetic_cooccurrence   Homology   Coexpression   experimentally_determined_Coexpression interaction   database_automated_annotated   combined_textmining   score
  --------- --------- -------------------------- -------------------------- ---------------------- ---------------------- ---------------------------- ------------- --------------------------- ---------- -------------- ---------------------------------------------------- ------------------------------ --------------------- -------
  CRY2      ARNTL     1860621                    1857849                    9606.ENSP00000406751   9606.ENSP00000374357   0                            0             0                           0          0.093          0.98                                                 0.9                            0.959                 0.999
  ARNTL     CRY1      1857849                    1842155                    9606.ENSP00000374357   9606.ENSP00000008527   0                            0             0                           0          0.093          0.986                                                0.9                            0.955                 0.999
  CRY2      PER2      1860621                    1844310                    9606.ENSP00000406751   9606.ENSP00000254657   0                            0             0                           0          0.154          0.995                                                0.9                            0.829                 0.999
  CRY2      PER1      1860621                    1849704                    9606.ENSP00000406751   9606.ENSP00000314420   0                            0             0                           0          0.054          0.98                                                 0.9                            0.824                 0.999
  PER1      CRY1      1849704                    1842155                    9606.ENSP00000314420   9606.ENSP00000008527   0                            0             0                           0          0.053          0.985                                                0.9                            0.781                 0.999
  PER2      CRY1      1844310                    1842155                    9606.ENSP00000254657   9606.ENSP00000008527   0                            0             0                           0          0.161          0.995                                                0.9                            0.926                 0.999
  ARNTL     PER1      1857849                    1849704                    9606.ENSP00000374357   9606.ENSP00000314420   0                            0             0                           0.626      0              0.967                                                0.9                            0.789                 0.997
  ARNTL     PER2      1857849                    1844310                    9606.ENSP00000374357   9606.ENSP00000254657   0                            0             0                           0.63       0              0.967                                                0.9                            0.968                 0.997
  PER1      PER2      1849704                    1844310                    9606.ENSP00000314420   9606.ENSP00000254657   0                            0             0                           0.844      0.073          0.97                                                 0.9                            0.661                 0.997
  CRY2      CLOCK     1860621                    1849105                    9606.ENSP00000406751   9606.ENSP00000308741   0                            0             0                           0          0.053          0.824                                                0.9                            0.835                 0.996
  CRY2      CRY1      1860621                    1842155                    9606.ENSP00000406751   9606.ENSP00000008527   0                            0             0.527                       0.981      0.072          0.967                                                0.9                            0.953                 0.996
  CLOCK     CRY1      1849105                    1842155                    9606.ENSP00000308741   9606.ENSP00000008527   0                            0             0                           0          0.053          0.697                                                0.9                            0.885                 0.996
  PER2      BHLHE41   1844310                    1843637                    9606.ENSP00000254657   9606.ENSP00000242728   0                            0             0                           0          0.053          0.981                                                0                              0.759                 0.995
  BHLHE41   CRY1      1843637                    1842155                    9606.ENSP00000242728   9606.ENSP00000008527   0                            0             0                           0          0.052          0.973                                                0                              0.782                 0.993
  ARNTL     CLOCK     1857849                    1849105                    9606.ENSP00000374357   9606.ENSP00000308741   0                            0             0                           0.687      0.094          0.873                                                0.9                            0.985                 0.991
  CLOCK     PER2      1849105                    1844310                    9606.ENSP00000308741   9606.ENSP00000254657   0                            0             0                           0.61       0.054          0.862                                                0.9                            0.833                 0.99
  CRY2      BHLHE41   1860621                    1843637                    9606.ENSP00000406751   9606.ENSP00000242728   0                            0             0                           0          0.052          0.968                                                0                              0.595                 0.987
  ARNTL     BHLHE40   1857849                    1844442                    9606.ENSP00000374357   9606.ENSP00000256495   0                            0             0                           0          0              0.436                                                0.9                            0.734                 0.983
  ARNTL     BHLHE41   1857849                    1843637                    9606.ENSP00000374357   9606.ENSP00000242728   0                            0             0                           0          0              0.156                                                0.9                            0.764                 0.978
  NR1H3     ABCA1     1859317                    1856172                    9606.ENSP00000387946   9606.ENSP00000363868   0                            0             0                           0          0              0.101                                                0.9                            0.777                 0.978
  CLOCK     BHLHE41   1849105                    1843637                    9606.ENSP00000308741   9606.ENSP00000242728   0                            0             0                           0          0              0.42                                                 0.9                            0.621                 0.976
  PER1      CLOCK     1849704                    1849105                    9606.ENSP00000314420   9606.ENSP00000308741   0                            0             0                           0.611      0.051          0.674                                                0.9                            0.591                 0.973
  CLOCK     BHLHE40   1849105                    1844442                    9606.ENSP00000308741   9606.ENSP00000256495   0                            0             0                           0          0              0.178                                                0.9                            0.527                 0.957
  BHLHE40   BHLHE41   1844442                    1843637                    9606.ENSP00000256495   9606.ENSP00000242728   0                            0             0                           0.858      0.181          0.36                                                 0.8                            0.759                 0.898
  NR1H3     SREBF1    1859317                    1853255                    9606.ENSP00000387946   9606.ENSP00000348069   0                            0             0                           0          0.049          0.36                                                 0                              0.837                 0.892
  ABCA1     SREBF1    1856172                    1853255                    9606.ENSP00000363868   9606.ENSP00000348069   0                            0             0                           0          0              0.088                                                0                              0.838                 0.846
  BHLHE40   CRY1      1844442                    1842155                    9606.ENSP00000256495   9606.ENSP00000008527   0                            0             0                           0          0.052          0.173                                                0                              0.758                 0.793
  BHLHE40   PER2      1844442                    1844310                    9606.ENSP00000256495   9606.ENSP00000254657   0                            0             0                           0          0.053          0.163                                                0                              0.733                 0.769
  NR1H3     CYP7A1    1859317                    1848316                    9606.ENSP00000387946   9606.ENSP00000301645   0                            0             0                           0          0.049          0.079                                                0                              0.742                 0.755
  ABCA1     CYP7A1    1856172                    1848316                    9606.ENSP00000363868   9606.ENSP00000301645   0                            0             0                           0          0              0.046                                                0                              0.694                 0.695
  SREBF1    CYP7A1    1853255                    1848316                    9606.ENSP00000348069   9606.ENSP00000301645   0                            0             0                           0          0.052          0                                                    0                              0.673                 0.677
  NR1H3     ARNTL     1859317                    1857849                    9606.ENSP00000387946   9606.ENSP00000374357   0                            0             0                           0          0              0.545                                                0                              0.193                 0.617
  CRY2      BHLHE40   1860621                    1844442                    9606.ENSP00000406751   9606.ENSP00000256495   0                            0             0                           0          0.052          0.173                                                0                              0.52                  0.59
  SREBF1    BHLHE40   1853255                    1844442                    9606.ENSP00000348069   9606.ENSP00000256495   0                            0             0                           0          0              0                                                    0                              0.483                 0.483
  PER1      BHLHE41   1849704                    1843637                    9606.ENSP00000314420   9606.ENSP00000242728   0                            0             0                           0          0              0                                                    0                              0.422                 0.422
  PER1      BHLHE40   1849704                    1844442                    9606.ENSP00000314420   9606.ENSP00000256495   0                            0             0                           0          0.053          0                                                    0                              0.364                 0.372
  ARNTL     SREBF1    1857849                    1853255                    9606.ENSP00000374357   9606.ENSP00000348069   0                            0             0                           0          0              0                                                    0                              0.34                  0.34
  SREBF1    CLOCK     1853255                    1849105                    9606.ENSP00000348069   9606.ENSP00000308741   0                            0             0                           0          0              0                                                    0                              0.304                 0.304
  ARNTL     CYP7A1    1857849                    1848316                    9606.ENSP00000374357   9606.ENSP00000301645   0                            0             0                           0          0              0                                                    0                              0.303                 0.303
  CLOCK     CYP7A1    1849105                    1848316                    9606.ENSP00000308741   9606.ENSP00000301645   0                            0             0                           0          0              0                                                    0                              0.25                  0.25
  CYP7A1    CRY1      1848316                    1842155                    9606.ENSP00000301645   9606.ENSP00000008527   0.074                        0             0                           0          0              0                                                    0                              0.213                 0.24
  SREBF1    CRY1      1853255                    1842155                    9606.ENSP00000348069   9606.ENSP00000008527   0                            0             0                           0          0              0                                                    0                              0.233                 0.232
  CRY2      CYP7A1    1860621                    1848316                    9606.ENSP00000406751   9606.ENSP00000301645   0.074                        0             0                           0          0              0                                                    0                              0.202                 0.229
  NR1H3     CLOCK     1859317                    1849105                    9606.ENSP00000387946   9606.ENSP00000308741   0                            0             0                           0          0              0                                                    0                              0.214                 0.214
  SREBF1    PER2      1853255                    1844310                    9606.ENSP00000348069   9606.ENSP00000254657   0                            0             0                           0          0              0                                                    0                              0.211                 0.211
  CRY2      SREBF1    1860621                    1853255                    9606.ENSP00000406751   9606.ENSP00000348069   0                            0             0                           0          0              0                                                    0                              0.204                 0.204
  SREBF1    BHLHE41   1853255                    1843637                    9606.ENSP00000348069   9606.ENSP00000242728   0                            0             0                           0          0              0                                                    0                              0.203                 0.203
  NR1H3     BHLHE40   1859317                    1844442                    9606.ENSP00000387946   9606.ENSP00000256495   0                            0             0                           0          0              0                                                    0                              0.194                 0.194
  NR1H3     PER2      1859317                    1844310                    9606.ENSP00000387946   9606.ENSP00000254657   0                            0             0                           0          0              0                                                    0                              0.194                 0.194
  ABCA1     BHLHE40   1856172                    1844442                    9606.ENSP00000363868   9606.ENSP00000256495   0                            0             0                           0          0              0.042                                                0                              0.191                 0.191
  CYP7A1    BHLHE41   1848316                    1843637                    9606.ENSP00000301645   9606.ENSP00000242728   0                            0             0                           0          0              0                                                    0                              0.166                 0.165
  ARNTL     ABCA1     1857849                    1856172                    9606.ENSP00000374357   9606.ENSP00000363868   0                            0             0                           0          0.09           0                                                    0                              0.111                 0.157
  CYP7A1    PER2      1848316                    1844310                    9606.ENSP00000301645   9606.ENSP00000254657   0                            0             0                           0          0              0                                                    0                              0.152                 0.151

###### 

Data of GO biological processes.

  Category           Term                                                                                                                        Count   \%         P-value        Genes                                                            List total   Pop hits   Pop total   Fold enrichment   Bonferroni      Benjamini      FDR
  ------------------ --------------------------------------------------------------------------------------------------------------------------- ------- ---------- -------------- ---------------------------------------------------------------- ------------ ---------- ----------- ----------------- --------------- -------------- --------------
  GOTERM_BP_DIRECT   GO:0032922\~circadian regulation of gene expression                                                                         8       72.73      4.21×10^−16^   CRY2, PER2, PER1, BHLHE40, ARNTL, BHLHE41, CRY1, CLOCK           11           57         16792       214.25            6.48×10^−14^    6.48×10^−14^   5.33×10^−13^
  GOTERM_BP_DIRECT   GO:2000323\~negative regulation of glucocorticoid receptor signaling pathway                                                5       45.45      9.51×10^−13^   CRY2, PER1, ARNTL, CRY1, CLOCK                                   11           6          16792       1,272.12          1.39×10^−10^    6.94×10^−11^   1.13×10^−09^
  GOTERM_BP_DIRECT   GO:0045892\~negative regulation of transcription, DNA-templated                                                             8       72.73      2.18×10^−09^   CRY2, PER2, PER1, BHLHE40, ARNTL, BHLHE41, CRY1, CLOCK           11           499        16792       24.47             3.18×10^−07^    1.06×10^−07^   2.59×10^−06^
  GOTERM_MF_DIRECT   GO:0070888\~E-box binding                                                                                                   5       45.45      2.85×10^−09^   PER1, BHLHE40, ARNTL, BHLHE41, CLOCK                             11           34         16881       225.68            2.08×10^−07^    2.08×10^−07^   2.98×10^−06^
  GOTERM_BP_DIRECT   GO:0042752\~regulation of circadian rhythm                                                                                  5       45.45      1.33×10^−08^   CRY2, PER2, PER1, CRY1, NR1H3                                    11           49         16792       155.77            1.94×10^−06^    4.84×10^−07^   1.58×10^−05^
  GOTERM_MF_DIRECT   GO:0000989\~transcription factor activity, transcription factor binding                                                     4       36.36      5.43×10^−08^   CRY2, PER2, PER1, CRY1                                           11           14         16881       438.47            3.96×10^−06^    1.98×10^−06^   5.67×10^−05^
  GOTERM_BP_DIRECT   GO:0007623\~circadian rhythm                                                                                                5       45.45      7.55×10^−08^   CRY2, PER2, PER1, ARNTL, CLOCK                                   11           75         16792       101.77            1.10×10^−05^    2.21×10^−06^   8.98×10^−05^
  GOTERM_BP_DIRECT   GO:0043153\~entrainment of circadian clock by photoperiod                                                                   4       36.36      1.72×10^−07^   CRY2, PER1, BHLHE40, CRY1                                        11           20         16792       305.31            2.52×10^−05^    4.20×10^−06^   2.05×10^−04^
  GOTERM_BP_DIRECT   GO:0000122\~negative regulation of transcription from RNA polymerase II promoter                                            7       63.64      1.10×10^−06^   CRY2, PER2, PER1, BHLHE40, BHLHE41, CRY1, NR1H3                  11           720        16792       14.84             1.61×10^−04^    2.30×10^−05^   1.31×10^−03^
  GOTERM_BP_DIRECT   GO:0006351\~transcription, DNA-templated                                                                                    9       81.82      1.21×10^−06^   CRY2, PER2, PER1, BHLHE40, ARNTL, BHLHE41, CRY1, CLOCK, NR1H3    11           1955       16792       7.03              1.76×10^−04^    2.20×10^−05^   1.43×10^−03^
  GOTERM_BP_DIRECT   GO:0042634\~regulation of hair cycle                                                                                        3       27.27      3.19×10^−06^   PER1, ARNTL, CLOCK                                               11           5          16792       915.92            4.65×10^−04^    5.17×10^−05^   3.79×10^−03^
  GOTERM_BP_DIRECT   GO:0042754\~negative regulation of circadian rhythm                                                                         3       27.27      1.15×10^−05^   CRY2, PER2, CRY1                                                 11           9          16792       508.85            1.67×10^−03^    1.67×10^−04^   1.36×10^−02^
  GOTERM_MF_DIRECT   GO:0000976\~transcription regulatory region sequence- specific DNA binding                                                  3       27.27      5.13×10^−04^   CRY2, PER2, ARNTL                                                11           58         16881       79.38             3.68×10^−02^    1.24×10^−02^   5.34×10^−01^
  GOTERM_MF_DIRECT   GO:0001047\~core promoter binding                                                                                           3       27.27      6.24×10^−04^   ARNTL, CRY1, CLOCK                                               11           64         16881       71.94             4.46×10^−02^    1.13×10^−02^   6.50×10^−01^
  GOTERM_BP_DIRECT   GO:0042632\~cholesterol homeostasis                                                                                         3       27.27      6.31×10^−04^   CYP7A1, ABCA1, NR1H3                                             11           64         16792       71.56             8.80×10^−02^    8.34×10^−03^   7.47×10^−01^
  GOTERM_BP_DIRECT   GO:0050796\~regulation of insulin secretion                                                                                 3       27.27      6.91×10^−04^   PER2, ARNTL, CLOCK                                               11           67         16792       68.35             9.60×10^−02^    8.38×10^−03^   8.19×10^−01^
  GOTERM_MF_DIRECT   GO:0043130\~ubiquitin binding                                                                                               3       27.27      9.26×10^−04^   CRY2, PER2, CRY1                                                 11           78         16881       59.02             6.54×10^−02^    1.34×10^−02^   9.62×10^−01^
  GOTERM_MF_DIRECT   GO:0000978\~RNA polymerase II core promoter proximal region sequence-specific DNA binding                                   4       36.36      9.91×10^−04^   PER1, BHLHE41, CLOCK, NR1H3                                      11           355        16881       17.29             6.99×10^−02^    1.20×10^−02^   1.03
  GOTERM_MF_DIRECT   GO:0003904\~deoxyribodipyrimidine photo-lyase activity                                                                      2       18.18      1.18×10^−03^   CRY2, CRY1                                                       11           2          16881       1,534.64          8.29 ×10^−02^   1.23×10^−02^   1.23
  GOTERM_MF_DIRECT   GO:0003914\~DNA (6-4) photolyase activity                                                                                   2       18.18      1.18×10^−03^   CRY2, CRY1                                                       11           2          16881       1,534.64          8.29×10^−02^    1.23×10^−02^   1.23
  GOTERM_MF_DIRECT   GO:0009882\~blue light photoreceptor activity                                                                               2       18.18      1.18×10^−03^   CRY2, CRY1                                                       11           2          16881       1,534.64          8.29×10^−02^    1.23×10^−02^   1.23
  GOTERM_BP_DIRECT   GO:0009785\~blue light signaling pathway                                                                                    2       18.18      1.19×10^−03^   CRY2, CRY1                                                       11           2          16792       1,526.55          1.60×10^−01^    1.33×10^−02^   1.41
  GOTERM_BP_DIRECT   GO:2000850\~negative regulation of glucocorticoid secretion                                                                 2       18.18      1.19×10^−03^   CRY2, CRY1                                                       11           2          16792       1,526.55          1.60×10^−01^    1.33×10^−02^   1.41
  GOTERM_CC_DIRECT   GO:0005634\~nucleus                                                                                                         9       81.81      1.48×10^−03^   CRY2, PER2, PER1, BHLHE40, ARNTL, BHLHE41, CRY1, CLOCK, NR1H3    11           5415       18224       2.75              3.63×10^−02^    3.63×10^−02^   1.19
  GOTERM_MF_DIRECT   GO:0003677\~DNA binding                                                                                                     6       54.55      1.57×10^−03^   CRY2, ARNTL, BHLHE41, CRY1, CLOCK, NR1H3                         11           1674       16881       5.50              1.08×10^−01^    1.42×10^−02^   1.62
  GOTERM_BP_DIRECT   GO:2000074\~regulation of type B pancreatic cell development                                                                2       18.18      1.79×10^−03^   ARNTL, CLOCK                                                     11           3          16792       1,017.70          2.30×10^−01^    1.85×10^−02^   2.10
  GOTERM_BP_DIRECT   GO:0097167\~circadian regulation of translation                                                                             2       18.18      2.39×10^−03^   PER2, PER1                                                       11           4          16792       763.27            2.94×10^−01^    2.29×10^−02^   2.79
  GOTERM_MF_DIRECT   GO:0043426\~MRF binding                                                                                                     2       18.18      2.96×10^−03^   BHLHE40, BHLHE41                                                 11           5          16881       613.85            1.95×10^−01^    2.37×10^−02^   3.05
  GOTERM_BP_DIRECT   GO:0010887\~negative regulation of cholesterol storage                                                                      2       18.18      3.57×10^−03^   ABCA1, NR1H3                                                     11           6          16792       508.85            4.07×10^−01^    3.21×10^−02^   4.16
  GOTERM_BP_DIRECT   GO:0051775\~response to redox state                                                                                         2       18.18      5.94×10^−03^   ARNTL, CLOCK                                                     11           10         16792       305.31            5.81×10^−01^    4.99×10^−02^   6.84
  GOTERM_CC_DIRECT   GO:0033391\~chromatoid body                                                                                                 2       18.18      6.57×10^−03^   ARNTL, CLOCK                                                     11           12         18224       276.12            1.52×10^−01^    7.91×10^−02^   5.21
  GOTERM_MF_DIRECT   GO:0001191\~transcriptional repressor activity, RNA polymerase II transcription factor binding                              2       18.18      7.09×10^−03^   BHLHE40, BHLHE41                                                 11           12         16881       255.77            4.05×10^−01^    5.06×10^−02^   7.16
  GOTERM_BP_DIRECT   GO:0071397\~cellular response to cholesterol                                                                                2       18.18      7.13×10^−03^   CYP7A1, ABCA1                                                    11           12         16792       254.42            6.48×10^−01^    5.64×10^−02^   8.15
  GOTERM_BP_DIRECT   GO:0010745\~negative regulation of macrophage derived foam cell differentiation                                             2       18.18      7.72×10^−03^   ABCA1, NR1H3                                                     11           13         16792       234.85            6.77×10^−01^    5.78×10^−02^   8.80
  GOTERM_BP_DIRECT   GO:0010875\~positive regulation of cholesterol efflux                                                                       2       18.18      8.31×10^−03^   ABCA1, NR1H3                                                     11           14         16792       218.08            7.04×10^−01^    5.91×10^−02^   9.44
  GOTERM_BP_DIRECT   GO:0006355\~regulation of transcription, DNA-templated                                                                      5       45.45      8.66×10^−03^   BHLHE40, ARNTL, BHLHE41, CLOCK, NR1H3                            11           1504       16792       5.07              7.19×10^−01^    5.87×10^−02^   9.82
  GOTERM_BP_DIRECT   GO:0018298\~protein-chromophore linkage                                                                                     2       18.18      9.50×10^−03^   CRY2, CRY1                                                       11           16         16792       190.82            7.51×10^−01^    6.13×10^−02^   10.71
  GOTERM_BP_DIRECT   GO:0050767\~regulation of neurogenesis                                                                                      2       18.18      1.13×10^−02^   PER2, ARNTL                                                      11           19         16792       160.69            8.09×10^−01^    6.94×10^−02^   12.59
  GOTERM_BP_DIRECT   GO:0070932\~histone H3 deacetylation                                                                                        2       18.18      1.24×10^−02^   PER2, PER1                                                       11           21         16792       145.39            8.39×10^−01^    7.33×10^−02^   13.82
  GOTERM_MF_DIRECT   GO:0000982\~transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding        2       18.18      1.35×10^−02^   ARNTL, CLOCK                                                     11           23         16881       133.45            6.30×10^−01^    8.65×10^−02^   13.27
  GOTERM_MF_DIRECT   GO:0043425\~bHLH transcription factor binding                                                                               2       18.18      1.35×10^−02^   BHLHE40, BHLHE41                                                 11           23         16881       133.45            6.30×10^−01^    8.65×10^−02^   13.27
  GOTERM_BP_DIRECT   GO:0019915\~lipid storage                                                                                                   2       18.18      1.42×10^−02^   CRY2, CRY1                                                       11           24         16792       127.21            8.76×10^−01^    8.02×10^−02^   15.63
  GOTERM_MF_DIRECT   GO:0003700\~transcription factor activity, sequence-specific DNA binding                                                    4       36.36      1.63×10^−02^   BHLHE40, ARNTL, CLOCK, NR1H3                                     11           961        16881       6.39              6.99×10^−01^    9.53×10^−02^   15.78
  GOTERM_BP_DIRECT   GO:0045944\~positive regulation of transcription from RNA polymerase II promoter                                            4       36.36      1.75×10^−02^   PER1, ARNTL, CLOCK, NR1H3                                        11           981        16792       6.22              9.24×10^−01^    9.44×10^−02^   18.93
  GOTERM_MF_DIRECT   GO:0016829\~lyase activity                                                                                                  2       18.18      1.88×10^−02^   CRY2, CRY1                                                       11           32         16881       95.91             7.50×10^−01^    1.01×10^−01^   17.97
  GOTERM_MF_DIRECT   GO:0001102\~RNA polymerase II activating transcription factor binding                                                       2       18.18      2.23×10^−02^   BHLHE40, BHLHE41                                                 11           38         16881       80.77             8.07×10^−01^    1.11×10^−01^   20.97
  GOTERM_MF_DIRECT   GO:0015485\~cholesterol binding                                                                                             2       18.18      2.40×10^−02^   ABCA1, NR1H3                                                     11           41         16881       74.86             8.31×10^−01^    1.12×10^−01^   22.42
  GOTERM_BP_DIRECT   GO:0031397\~negative regulation of protein ubiquitination                                                                   2       18.18      2.42×10^−02^   PER2, CRY1                                                       11           41         16792       74.47             9.72×10^−01^    1.24×10^−01^   25.22
  GOTERM_MF_DIRECT   GO:0001046\~core promoter sequence-specific DNA binding                                                                     2       18.18      2.52×10^−02^   CRY1, CLOCK                                                      11           43         16881       71.38             8.45×10^−01^    1.10×10^−01^   23.38
  GOTERM_BP_DIRECT   GO:0006094\~gluconeogenesis                                                                                                 2       18.18      2.59×10^−02^   PER2, CRY1                                                       11           44         16792       69.39             9.78×10^−01^    1.28×10^−01^   26.80
  GOTERM_MF_DIRECT   GO:0019902\~phosphatase binding                                                                                             2       18.18      2.63×10^−02^   CRY2, CRY1                                                       11           45         16881       68.21             8.58×10^−01^    1.08×10^−01^   24.32
  GOTERM_MF_DIRECT   GO:0031490\~chromatin DNA binding                                                                                           2       18.18      3.38×10^−02^   PER1, CLOCK                                                      11           58         16881       52.92             9.19×10^−01^    1.30×10^−01^   30.17
  GOTERM_CC_DIRECT   GO:0043231\~intracellular membrane-bounded organelle                                                                        3       27.27      3.58×10^−02^   CYP7A1, ARNTL, CLOCK                                             11           558        18224       8.91              5.98×10^−01^    2.62×10^−01^   25.59
  GOTERM_BP_DIRECT   GO:0045893\~positive regulation of transcription, DNA-templated                                                             3       27.27      3.59×10^−02^   ARNTL, CLOCK, NR1H3                                              11           515        16792       8.89              9.95×10^−01^    1.68×10^−01^   35.24
  GOTERM_MF_DIRECT   GO:0043565\~sequence-specific DNA binding                                                                                   3       27.27      3.59×10^−02^   ARNTL, CLOCK, NR1H3                                              11           518        16881       8.89              9.31×10^−01^    1.31×10^−01^   31.74
  GOTERM_MF_DIRECT   GO:0003705\~transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding                      2       18.18182   3.84×10^−02^   BHLHE40, BHLHE41                                                 11           66         16881       46.50             9.43×10^−01^    1.33×10^−01^   33.57
  GOTERM_BP_DIRECT   GO:0032868\~response to insulin                                                                                             2       18.18      3.92×10^−02^   CRY2, CRY1                                                       11           67         16792       45.57             9.97×10^−01^    1.77×10^−01^   37.83
  GOTERM_BP_DIRECT   GO:0042593\~glucose homeostasis                                                                                             2       18.18      5.86×10^−02^   CRY2, CRY1                                                       11           101        16792       30.22             9.99×10^−01^    2.47×10^−01^   51.19
  GOTERM_MF_DIRECT   GO:0042826\~histone deacetylase binding                                                                                     2       18.18      5.88×10^−02^   BHLHE41, CRY1                                                    11           102        16881       30.09             9.88×10^−01^    1.90×10^−01^   46.89
  GOTERM_MF_DIRECT   GO:0001078\~transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding   2       18.18      6.39×10^−02^   BHLHE40, BHLHE41                                                 11           111        16881       27.65             9.92×10^−01^    1.97×10^−01^   49.78
  GOTERM_BP_DIRECT   GO:0071222\~cellular response to lipopolysaccharide                                                                         2       18.18      6.53×10^−02^   ABCA1, NR1H3                                                     11           113        16792       27.02             9.99×10^−01^    2.65×10^−01^   55.19
  GOTERM_MF_DIRECT   GO:0005515\~protein binding                                                                                                 9       81.82      7.05×10^−02^   CRY2, PER2, BHLHE40, ARNTL, ABCA1, BHLHE41, CRY1, CLOCK, NR1H3   11           8785       16881       1.57              9.95×10^−01^    2.07×10^−01^   53.38
  GOTERM_BP_DIRECT   GO:0051726\~regulation of cell cycle                                                                                        2       18.18      7.15×10^−02^   PER2, ARNTL                                                      11           124        16792       24.62             9.99×10^−01^    2.80×10^−01^   58.57
  GOTERM_MF_DIRECT   GO:0046983\~protein dimerization activity                                                                                   2       18.18      8.55×10^−02^   ARNTL, CLOCK                                                     11           150        16881       20.46             9.99×10^−01^    2.38×10^−01^   60.62

GO, Gene Ontology; FDR, false discovery rate.

###### 

Data of KEGG pathways analysis.

  Term                                      Database       ID         Input number   Background number   P-value        Corrected P-value   Input                                            Hyperlink
  ----------------------------------------- -------------- ---------- -------------- ------------------- -------------- ------------------- ------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Circadian rhythm                          KEGG PATHWAY   hsa04710   8              31                  6.53×10^−23^   9.80×10^−22^        8864\|5187\|8553\|406\|1408\|9575\|79365\|1407   <http://www.genome.jp/kegg-bin/show_pathway?hsa04710/hsa:8553%09red/hsa:9575%09red/hsa:406%09red/hsa:1408%09red/hsa:5187%09red/hsa:8864> %09red/hsa:79365%09red/hsa:1407%09red
  Herpes simplex infection                  KEGG PATHWAY   hsa05168   4              186                 1.62×10^−07^   1.22×10^−06^        406\|8864\|5187\|9575                            <http://www.genome.jp/kegg-bin/show_pathway?hsa05168/hsa:9575%09red/hsa:406%09red/hsa:8864%09red/hsa:5187%09red>
  PPAR signaling pathway                    KEGG PATHWAY   hsa03320   2              72                  1.86×10^−04^   9.29×10^−04^        10062\|1581                                      <http://www.genome.jp/kegg-bin/show_pathway?hsa03320/hsa:1581%09red/hsa:10062%09red>
  Circadian entrainment                     KEGG PATHWAY   hsa04713   2              95                  3.19×10^−04^   1.20×10^−04^        8864\|5187                                       <http://www.genome.jp/kegg-bin/show_pathway?hsa04713/hsa:8864%09red/hsa:5187%09red>
  Dopaminergic synapse                      KEGG PATHWAY   hsa04728   2              130                 5.90×10^−04^   1.77×10^−03^        406\|9575                                        <http://www.genome.jp/kegg-bin/show_pathway?hsa04728/hsa:9575%09red/hsa:406%09red>
  Primary bile acid biosynthesis            KEGG PATHWAY   hsa00120   1              17                  4.97×10^−03^   1.24×10^−02^        1581                                             <http://www.genome.jp/kegg-bin/show_pathway?hsa00120/hsa:1581%09red>
  Fat digestion and absorption              KEGG PATHWAY   hsa04975   1              41                  1.16×10^−02^   2.37×10^−02^        19                                               <http://www.genome.jp/kegg-bin/show_pathway?hsa04975/hsa:19%09red>
  ABC transporters                          KEGG PATHWAY   hsa02010   1              45                  1.27×10^−02^   2.37×10^−02^        19                                               <http://www.genome.jp/kegg-bin/show_pathway?hsa02010/hsa:19%09red>
  Steroid hormone biosynthesis              KEGG PATHWAY   hsa00140   1              58                  1.62×10^−02^   2.70×10^−02^        1581                                             <http://www.genome.jp/kegg-bin/show_pathway?hsa00140/hsa:1581%09red>
  Bile secretion                            KEGG PATHWAY   hsa04976   1              71                  1.97×10^−02^   2.96×10^−02^        1581                                             <http://www.genome.jp/kegg-bin/show_pathway?hsa04976/hsa:1581%09red>
  Insulin resistance                        KEGG PATHWAY   hsa04931   1              109                 3.00×10^−02^   4.09×10^−02^        10062                                            <http://www.genome.jp/kegg-bin/show_pathway?hsa04931/hsa:10062%09red>
  Hepatitis C                               KEGG PATHWAY   hsa05160   1              133                 3.65×10^−02^   4.56×10^−02^        10062                                            <http://www.genome.jp/kegg-bin/show_pathway?hsa05160/hsa:10062%09red>
  Non-alcoholic fatty liver disease         KEGG PATHWAY   hsa04932   1              151                 4.13×10^−02^   4.76×10^−02^        10062                                            <http://www.genome.jp/kegg-bin/show_pathway?hsa04932/hsa:10062%09red>
  Transcriptional misregulation in cancer   KEGG PATHWAY   hsa05202   1              180                 4.89×10^−02^   5.24×10^−02^        8864                                             <http://www.genome.jp/kegg-bin/show_pathway?hsa05202/hsa:8864%09red>
  Metabolic pathways                        KEGG PATHWAY   hsa01100   1              1,243               2.95×10^−01^   2.95×10^−01^        1581                                             <http://www.genome.jp/kegg-bin/show_pathway?hsa01100/hsa:1581%09red>

Data from the KEGG pathway database. The statistical methods used were the hypergeometric and Fisher\'s exact tests. The Benjamini and Hochberg FDR correction method was applied. KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.
